- Danish stocks
- First North Copenhagen
- Bavarian Nordic
- Chr. Hansen
- DanDrit Biotech
- GN Store Nord
- Novo Nordisk
- Veloxis Pharmaceuticals
- William Demant
- Zealand Pharma
- Norwegian stocks
- Swedish stocks
- A1M Pharma
- Accelerator Nordic
- Clinical Laserthermia
- Eurocine Vaccines
- European Inst. of Science
- IDL Biotech
- Medfield Diagnostics
- Micropos Medical
- Rubicon Life Science
- SPAGO Imaging
- Vivoline Medical
- First North Stockholm
- OMX Stockholm A-F
- OMX Stockholm G-Z
- US stocks
- General discussion
- All posts
BioPorto, The NGAL Test: Implementation into routine diagnostics, when?
By ndrs On 19. March 2013 · 2 Comments · In BioPorto
Below are a couple of videos which hopefully may initiate a lengthy discussion about the value of novel biomarkers to diagnose acute kidney injury and if/when we might see these implemented into routine diagnostics.
“Biomarkers For Early Risk Assessment Of Acute Kidney Injury” :
“Novel Biomarkers for Acute Kidney Injury” :
“2012 ESICM Symposium – New AKI Biomarkers – Panel Discussion 1” :
There are quite a few youtube videos to be found relating to AKI and biomarkers, several, like the last one posted above, from ESICM (European Society of Intensive Care Medicine) 2012 – please do have a look and return here to discuss!
ISICEM (International Symposium on Intensive Care and Emergency Medicine) 2013 is held from today to March 22nd in Brussels.
- The NGAL Test at Hvidovre Hospital Symposium about NGAL at Hvidovre Hospital, Copenhagen Senior Consultant and...
- 2013 a breakthrough year for BioPorto and the NGAL-Test If one is to believe Bioporto’s distributors – then 2013...
- The NGAL Test i rutine diagnostikken. Hvor mange drejer det sig om? ‘Nyheden’ fra Bioportos egen distributørkongres har vist som som et...
- Not so Rapid expansion of NGAL test In another article the expansion of NGAL Test is not...
- The NGAL Test™ Distributor Forum, November 13th 2012, Düsseldorf, Germany (A must read) For et par måneder siden hapsede jeg lidt frækt fra...
2 Responses to BioPorto, The NGAL Test: Implementation into routine diagnostics, when?
Leave a Reply Cancel reply
- Lesliejek on Chat transcript regarding the NGAL distr. Agreement with the Wiener Group. (In danish)
- Patrickciz on Chat transcript regarding the NGAL distr. Agreement with the Wiener Group. (In danish)
- Jameskipse on Chat transcript regarding the NGAL distr. Agreement with the Wiener Group. (In danish)
- Rickiehiela on Chat transcript regarding the NGAL distr. Agreement with the Wiener Group. (In danish)
- James Rolitson on Good Discussion on Bronte Capital’s long thesis on Herbalife
thanks SA – we'll add this article to our library…
More on NGAL – "The strength of NGAL in prediction of AKI" :